UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/550,152	01/04/2007	Joacim Elmen	22460-0041001 / 1019US	1052	
	7590 03/03/201 ARDSON P.C. (BO)	1	EXAMINER		
P.O. BOX 1022			VIVLEMORE, TRACY ANN		
MINNEAPOLI	S, MN 55440-1022		ART UNIT PAPER NUMBER		
			1635		
			NOTIFICATION DATE	DELIVERY MODE	
			03/03/2011	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

	Application No.	Applicant(s)	
	10/550,152	ELMEN ET AL.	
Office Action Summary	Examiner	Art Unit	
	Tracy Vivlemore	1635	
The MAILING DATE of this communication appeariod for Reply	ppears on the cover sheet w	th the correspondence addres	s
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perior. Failure to reply within the set or extended period for reply will, by statu. Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNION. 1.136(a). In no event, however, may a red will apply and will expire SIX (6) MONute, cause the application to become AE	CATION. eply be timely filed ITHS from the mailing date of this commur BANDONED (35 U.S.C. § 133).	
Status			
 1) Responsive to communication(s) filed on 14 2a) This action is FINAL. 2b) Th 3) Since this application is in condition for allow closed in accordance with the practice under 	nis action is non-final. rance except for formal matt	•	rits is
Disposition of Claims			
4) ☑ Claim(s) 67-97 and 102 is/are pending in the 4a) Of the above claim(s) is/are withdr 5) ☐ Claim(s) is/are allowed. 6) ☒ Claim(s) 67-97 and 102 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and.	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examir 10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examir 11).	ccepted or b) objected to e drawing(s) be held in abeyar ection is required if the drawing	ice. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.	, ,
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in A iority documents have been au (PCT Rule 17.2(a)).	pplication No received in this National Stag	ge
Attachment(s)	» —	(DTG 446)	
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s	Summary (PTO-413) s)/Mail Date. nformal Patent Application 	

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Any rejection or objection not reiterated in this Action is withdrawn.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 67-97 and 102 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of Crooke (US 6,107,094) and Orum et al. (US 2002/0068709).

Application/Control Number: 10/550,152

Page 3

Art Unit: 1635

Crooke teaches at column 12 oligomeric compounds that bind to a target RNA strand and are substrates for dsRNase enzymes. The oligomeric compounds include oligoribonucleotides and other oligomeric compounds having a linear sequence of linked ribonucleoside subunits incorporated therein. The oligoribonucleotides are assembled from a plurality of nucleoside subunits. In certain preferred embodiments at least one of the nucleoside subunits bears a substituent group that increases the binding affinity of the oligoribonucleotide for a complementary strand of nucleic acid. In certain embodiments of the invention, specific nucleoside subunits or internucleoside linkages are functionalized or selected to increase the nuclease resistance of the oligoribonucleotide or oligoribonucleoside. At column 14 Crooke teaches that the oligomeric compounds of the invention are preferably 15-25 nucleotides in length. One embodiment of oligomeric compounds specifically taught by Crooke in examples 24 and 27a are artificial substrates for dsRNAse enzymes. These substrates comprise sense and antisense strands wherein one or both strands are chemically modified. Crooke exemplifies embodiments where the artificial substrate is 17 and 20 nucleotides in length. Crooke does not teach LNAs as a modified nucleoside subunit.

Orum et al. teach that to be useful an oligonucleotide must have properties such as good resistance to extra- and intracellular nucleases as well as high affinity and specificity for the target. Orum et al. further teach that DNA compounds referred to as Locked Nucleic Acids, which have bicyclic sugars, provide extremely stable duplexes with a target nucleic acid.

Page 4

It would have been obvious to one of ordinary skill in the art at the time the invention was made to produce the artificial nuclease substrates of Crooke with one or more LNA monomers as taught by Orum et al. Based on the disclosure explicit teachings of Crooke of artificial substrates that contain modified nucleotides and his teaching that modifications are intended to increase nuclease resistance and/or binding affinity of the oligoribonucleotide for a complementary strand of nucleic acid the person of ordinary skill in the art would have reason to make modified substrates and based on the teachings of Orum et al. that inclusion of LNA monomers provide nuclease resistance and extremely stable duplexes the person of ordinary skill would be motivated to make the modified substrate with one or more LNA monomers. Based on the broad disclosure of Crooke one of ordinary skill would recognize the inclusion of multiple LNA moieties and the placement of these moieties to be a matter of design choice.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-2914. The examiner can normally be reached on Mon-Fri 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Heather Calamita, can be reached on 571-272-2876. The central FAX Number is 571-273-8300.

Application/Control Number: 10/550,152 Page 5

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Tracy Vivlemore Primary Examiner Art Unit 1635

/Tracy Vivlemore/ Primary Examiner, Art Unit 1635